Aerin Medical
- Industry
- Medical Devices & Equipment
- Founded Year
- 2011
- Headquarters
- Mountain View, California, United States
- Employee Count
- 176
Key People
- Matt Brokaw - President & CEO
- Scott J. Wolf - Founder
- Fred Dinger - COO
- Irina Ridley - Chief Legal Officer
- Kevin Reilly - Board Member
- Nael Kassar - Board Member
- William Facteau - Board Member
- Greg Garfield - Board Member
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in the MedTech industry.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: Aerin Medical addresses significant unmet needs in treating nasal airway obstruction and chronic rhinitis.
By targeting common nasal conditions with non-invasive solutions, Aerin Medical meets a critical clinical need, potentially improving patient outcomes and quality of life.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has several players offering treatments for nasal conditions, though Aerin's non-invasive approach differentiates it.
The ENT device market includes various competitors; however, Aerin's proprietary temperature-controlled technology offers a less invasive alternative, potentially appealing to both physicians and patients.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves established radiofrequency techniques, suggesting manageable technical challenges.
Leveraging existing radiofrequency technology allows for a more predictable development process, minimizing unforeseen technical hurdles.
- Patent
-
Aspect: Strong
Summary: Aerin Medical holds patents for its proprietary temperature-controlled technology.
Strong patent protection safeguards Aerin's innovations, potentially preventing competitors from replicating their technology and ensuring market exclusivity.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors, totaling over $200 million.
Substantial funding from established investors enables Aerin Medical to invest in product development, clinical trials, and market expansion, positioning the company for sustained growth.
- Regulatory
-
Aspect: 510k/PMA
Summary: Aerin's products have received FDA clearance, facilitating market entry.
Obtaining FDA clearance indicates compliance with safety and efficacy standards, allowing Aerin Medical to market its products in the U.S. and potentially paving the way for international approvals.
Opportunity Rollup
- Odds of Success
- 4.3
- Peak Market Share
- 5.9
- Segment CAGR
- 7.7%
- Market Segment
- ENT Devices
- Market Sub Segment
- Balloon Sinuplasty System
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.30 |
| 2 | 0.88 |
| 3 | 2.06 |
| 4 | 4.13 |
| 5 | 5.90 |
Key Takeaway
Aerin Medical's innovative, non-invasive solutions for nasal conditions, backed by strong leadership and substantial funding, position the company favorably in a growing market, despite competitive and regulatory challenges.